13th International Congress on Spondyloarthritis

7 – 9 September 2022
Ghent, Belgium

www.spa-congress.org

Final Programme
Dear colleagues and friends,

Welcome to the 13th International Congress on Spondyloarthritides, which will take place on the 7 – 9 September 2022 in the beautiful city of Gent as a wholly in-person meeting. The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. Indeed, the attendance has almost quadrupled since 1998 to include scientists, medical doctors, allied health professionals, pharmaceutical industry representatives and people affected by these conditions from all over the world.

The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters.

The programme for the 2022 congress will offer a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics. A highly regarded part of the meeting are the poster sessions which provide the perfect frame for stimulating and interactive multidisciplinary exchanges among attendees. This year will mark the first year that we will have poster tours for each of the sessions. In addition, we have planned lively debates on highly controversial topics in clinical and basic science which promise to be educational as well as entertaining.

The “Gent Oration” - aimed to honor a scientist or clinician who is recognized internationally as having made major contributions throughout their career - will be given by Professor Jürgen Braun.

The social programme including the Walking Dinner at the Opening Reception, Gala dinner and Farewell Drink are sure to give you the opportunity to catch up with old and new friends and enjoy the magic of Gent.

As co-presidents of the 13th International Congress on Spondyloarthritides we would like to welcome you to this exciting occasion which we are sure will once again, provide the best platform for vibrant scientific and clinical discussions in all aspects of these fascinating group of diseases.

Francesco Ciccia and Walter P. Maksymowych
Congress Presidents
Wednesday 7 September

Welcome Address
Francesco Ciccia and Walter P. Maksymowych, Congress Presidents

SESSION 1: State-of-the-Art Symposium
13.00 INV1 A risk benefit analysis of JAKi in rheumatology
Jasvinder Singh, USA

13.30 INV2 JAKi-mechanism of action: What explains their efficacy in SpA?
Massimo Gadina, USA

SESSION 2: Basic Science: Stromal Cells and Innate Immunity in SpA Pathogenesis
14.00 INV3 The stromal code in SpA
Rik Lories, Belgium

14.20 INV4 Stromal cells: Commanders of joint inflammation, or innocent bystanders?
Eric Gracey, Belgium

14.40 INV5 MIF-neutrophil-bone axis in AS pathogenesis
Nigil Haroon, Canada

15.00 Coffee Break and Poster Session A

SESSION 3: Innovations in Core Outcomes
16.00 INV6 The Updated ASAS Core Set: What are the controversies and remaining unmet needs?
Victoria Navarro-Compan, Spain

16.20 INV7 Novel biomarker technologies for axSpA: Lessons learned from RA and PsA
Hussein Al-Mossawi, UK

Selected Oral Presentations I: Treatment of SpA
16.40 O1 ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofia Ramiro, Leiden & Heerlen, The Netherlands

16.55 O2 Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: Efficacy and safety up to week 24 from the BE MOBILE phase 3 studies
Xenofon Baraliakos, Bochum, Germany

17.10 O3 Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis (consul): An open-label, randomized controlled, multicenter trial
Fabian Proff, Berlin, Germany

17.25 O4 Recapture rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: Results at week 104 from a randomized placebo-controlled withdrawal study
Robert Landewé, Amsterdam, The Netherlands

17.40 Grand Debate
Moderator: Francesco Ciccia, Italy

INV8 Motion: The primary etiopathological lesion in axial spondyloarthritis is enthesitis
Dennis McGonagle, UK

INV9 Counter motion: The primary etiopathological lesion in axial spondyloarthritis is marrow-centric
Walter P. Maksymowych, Canada

18.30 Opening Reception and Walking Dinner
Thursday 8 September

The Ghent SpA Oration
Chair: Walter P. Maksymowych, Canada

08.30 INV10 What happened in the field of axial spondyloarthritis in the last decades? A personal view
Jürgen Braun, Germany

Selected Oral Presentations II: Epidemiology and Imaging

09.30 O5 The prevalence of inflammatory back pain and HLA-B27 in a large population-based cohort in the Netherlands
Stan Kieskamp, Groningen, The Netherlands

09.45 O6 A machine learning pipeline for prediction of bone marrow oedema along the sacroiliac joints on magnetic resonance imaging
Joris Roels, Ghent, Belgium

An AI-based algorithm for automatic detection of erosion and ankylosis on CT images of the sacroiliac joints: Multicentre development and validation
Thomas Van Den Berghe, Ghent, Belgium

10.00 O7 Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study
Diego Benavent, Madrid, Spain

10.30 Coffee Break and Poster Session B

SESSION 4: Gut Corner

11.30 INV11 Gut ache: The outcome of dysbiosis in the joint
Ranjeny Thomas, Australia

11.50 INV12 Investigating the microbiota in gut and joint disease using transgenic & germ-free mouse technology
Lars Vereecke, Belgium

12.10 INV13 Decrypting the conundrum of intestinal inflammation in AS pathogenesis
Daniele Mauro, Italy

12.30 Lunch

Thursday 8 September

Keynote Basic Science Lecture
Chair: Francesco Ciccia, Italy

13.30 INV14 Advances in fibroblast biology that impact spondyloarthritis
Chris Buckley, UK

Selected Oral Presentations III: Pathogenesis of SpA

14.10 O9 MIF is an important mediator in SpA associated gut inflammation in SKG mouse
Shaghayegh Foroozan Boroojeni, Toronto, Canada

14.25 O10 High dimensional immunophenotyping of peripheral blood populations by mass cytometry in axial spondyloarthritis
Claudia Worth, Oxford, UK

14.40 O11 Mechanical loading-induced BHLHE40 promotes inflammatory arthritis
Eric Gracey, Ghent, Belgium

14.55 O12 Single cell analysis of ankylosing spondylitis synovial T cells identifies CD8 and TREG clonal expansion and phenotypic patterns of tissue adaptation
Davide Simone, Oxford, UK

15.10 O13 Reduced frequency of RORγT regulatory T cells in axial spondyloarthritis: Effect of secukinumab treatment
Addison C. Pacheco, Toronto, Canada

15.25 Coffee Break and Poster Session C

16.30 Grand Debate
Moderator: Walter P. Maksymowych

Motion: Axial inflammation in PsA is distinct from axSpA

INV15 (PRO) Dafna Gladman, Canada
INV16 (CON) Robert Landewé, The Netherlands

17.15 End of day 2
Friday 9 September

Session 5: Therapeutics Corner

08.30  INV17 Priority targets from early phase trials in SpA and PsA
Iain McInnes, UK

08.50  INV18 Common pitfalls in the analysis and interpretation of axSpA RCTs
Alexandre Sepriano, Portugal

09.10  INV19 Emerging technologies in drug delivery: The promise of nanotherapeutics
Hua Pan, USA

Flash Oral Presentations IV: Treatment, Epidemiology, and Imaging

09.30  O14 Do fatty lesions explain the association between inflammation and new syndesmophytes in patients with radiographic axial spondyloarthritis?
Roos Stal, Leiden, The Netherlands

09.37  O15 A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis
Robin Besuyen, Leiden, The Netherlands

09.44  O16 Comorbidities in early psoriatic arthritis: Belgian prospective METAPSA cohort
Alla Ishchenko, Antwerp, Belgium

09.51  O17 Bimekizumab in BDMARD-naïve patients with psoriatic arthritis: 24-week efficacy & safety from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study
Robert Landewé, Amsterdam, The Netherlands

09.58  O18 MRI spinal lesions in patients without MRI or radiographic lesions in the sacroiliac joints typical of axial spondyloarthritis
Walter Maksymowych, Edmonton, Canada

10.05  O19 Pathogenicity of IL-17 producing cells in HBLA-B27 transgenic rat model of spondyloarthritis
Marie Beaufrère, Paris & Boulogne-Billancourt, France

10.15  Coffee Break and Poster Session D

Session 6: Genetics Corner

11.15  INV20 Family studies in Axial Spondyloarthritis: What have we learnt?
Félicie Costantino, France

11.40  INV21 Genomic dissection of the causes of ankylosing spondylitis
Matthew Brown, UK

12.05  INV22 From GWAS to function: Using functional genomics to identify the mechanisms underlying ankylosing spondylitis
Matteo Vecellio, UK

Session 7: Imaging Corner

12.20  INV23 What does molecular imaging tell us about tissue reparation in axSpA?
Andreas Ramming, Germany

12.40  INV24 Trials and tribulation of CT in axSpA: Is there a final verdict?
Torsten Diekhoff, Germany

13.00  INV25 Artificial intelligence, machine learning and radiomics for imaging in rheumatology
Berend Stoel, The Netherlands

13.35  Farewell Reception
Poster session A is during the coffee break of 15.10 – 16.10 hrs on Wednesday, September 7. The presenters of the posters P1 through P24 are requested to be present at their posters.

**P1** Work participation and productivity is unaffected in Belgian spondyloarthritis patients compared to the general population: Data from the BelGian Inflammatory Arthritis and Spondylitis cohort (Be-GIANT)
De Craemer A., Deroo L., Renson T., Desimpele I., Delmez L., Decuman S., Janssens X., Boonean A., Elewaut D., Carron P., Van den Bosch F. (Belgium & The Netherlands)

**P2** Development of international consensus on a standardized image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI – an ASAS-SPARTAN collaboration

**P3** Magnetic resonance imaging characteristics of spine and sacroiliac joints in patients with psoriatic arthritis and axial manifestations
Baraliakos X., Pournara E., Coates L.C., Blanco R., O’Brien E., Schulz B., Navarro-Compán V., Landewé R. (Germany, Switzerland, UK, Spain, Ireland & The Netherlands)

**P4** Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis - Results from fifteen countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network

**P5** Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis - Results from thirteen countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network

**P6** Comparison of established and new, preliminarily proposed ASAS cut-offs for inflammatory MRI lesions in the sacroiliac joints in axial spondyloarthritis and implications for recruitment in clinical studies
Baraliakos X., Machado P.M., Bauer L., Hoepken B., Kim M., Kumte T., Tham R., Rudwaleit M. (Germany, UK & USA)

**P7** Bimekizumab in bDMARD-naïve patients with psoriatic arthritis: Interim analysis of inhibition of radiographic structural progression at 16 weeks of treatment in BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study

**P8** Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy & safety from BE COMPLETE, a phase 3, multicentre, randomised placebo-controlled study

**P9** The impact of MRI slice thickness on the detection of spinal syndesmophytes in axial spondyloarthritis
Klavdianou K., Mewes A.D., Tsiami S., Sewerin P., Baraliakos X. (Germany & Greece)
P10  Pain response in psoriatic arthritis patients treated with guselkumab is driven predominantly by inflammation-independent effects
Mease P.J., Soriano E.R., Chakravarty S.D., Rampakakis E., Shawi M., Nash P., Rahman P. (USA, Argentina, Canada & Australia)

P11  Genetic and molecular distinctions between axial psoriatic arthritis and ankylosing spondylitis
Kavanaugh A., Baraliakos X., Gao S., Chen W., Sweet K., Chakravarty S.D., Song Q., Shawi M., Behrens F., Rahman P. (USA, Germany & Canada)

P12  Radiographic progression from non-radiographic to radiographic axial spondyloarthritis: Results from a 5-year multicountry prospective observational study
Pod Dubyn D., Siener J., Akar S., Muñoz-Fernández S., Haibel H., Diekhoff T., Protopopov M., Altmaier E., Ganz F., Inman R.D. (Germany, Turkey, Spain, Switzerland & Canada)

P13  Is radiographic axial involvement associated with syndesmophyte development after 2 years in PsA patients

P14  Tissue tropism in T cell dependent regulatory pathways controlling TNF driven SpA-like joint and gut pathology

P15  IL-23 induced GDF15 contributes to trabecular bone loss, but does not affect skin, gut or joint inflammation
Van der Cruysse R., Gaublomme D., Dumas E., Stappers F., Coudens J., Decruy T., Vereecke L., Gracey E., Elewaut D. (Belgium)

P16  Deep immune profiling of cytotoxic T cells (CTL) from patients with ankylosing spondylitis revealed a subset of CTL Co-expressing PD-1 and TIGIT that resists immune exhaustion
Tang M., Pacheco A.C., Qaiyum Z., Lim M., Inman R.D. (Canada)

P17  Validation of the SPARCC MRI-RETIC E-Tool for increasing scoring proficiency of MRI lesions in axial spondyloarthritis

P18  Elevated complement proteins in patients with axSpA compared with appropriate controls with low back pain with and without SpA-features

P19  Semiquantitative assessment of synovitis on US-guided synovial membrane biopsies is contingent on disease phase and predictive of treatment response in naive to treatment psoriatic arthritis

P20  Direct and indirect effect of TNF inhibitors on spinal mobility in people with axial spondyloarthritis (axSpA) and the mediator role of disease activity
Pinto A.S., Yao C., Hayward R., Keat A., Machado P.M. (Portugal & UK)

P21  IL-4 and IL-13 modulate enthesal IL-23 production and blockade with dupilumab is associated with emergent Th17 type diseases

P22  Single cell analysis of the response of axial spondyloarthritis to TNFi therapy
Jin L., Curion F., Penkava F., Chen L., Attar M., Bowden R., Bowness P., Sansom S.N. (UK, Germany & Australia)

P23  Prevalence of axSpA in patients treated for chronic back pain in chiropractic clinics: The Oregon Chiropractic Axial Spondyloarthritis Study (ORCAS) – An interim analysis

P24  Comparison of sacroiliac CT findings in patients with and without Psoriatic Arthritis: results of the CASIPS Study
Fakhri O., Ramon A., Prati C., Ornetti P., Wendling D., Verhoeven F. (France)
Poster Session B

Poster session B is during the coffee break of 10.30 – 11.30 hrs on Thursday, September 8. The presenters of the posters P25 through P48 are requested to be present at their posters.

**P25** Psoriasis, without rheumatological manifestations, is associated with structural changes of the sacroiliac joint, a controlled study using CT scan
Leriche T., Fakih O., Aubin F., Chouk M., Prati C., Wendling D., Verhoeven F. (France)

**P26** Effect of tofacitinib and glucocorticoids on intestinal permeability, epithelial damage and bacterial translocation in rat adjuvant-induced arthritis
Hecquet S., Totoson P., Tournier M., Prati C., Wendling D., Demougeot C., Verhoeven F. (France)

**P27** Immunological differences between psoriatic arthritis patients who are tumor necrosis factor inhibitor-naïve and who have inadequate response to tumor necrosis factor inhibitors
Siebert S., Coates L.C., Schett G., Raychaudhuri S.P., Chen W., Gao S., Chakravarty S.D., Shawi M., Lavie F., Theander E., Neuhold M., Kollmeier A.P., Xu X.L., Rahman P., Mease P.J., Deodhar A. (UK, Germany, USA, France, Sweden, Switzerland & Canada)

**P28** Effect of guselkumab on serum biomarkers in psoriatic arthritis patients with inadequate response or intolerance to tumor necrosis factor inhibitors: Results from the COSMOS study
Schett G., Chen W., Gao S., Chakravarty S.D., Shawi M., Lavie F., Theander E., Neuhold M., Coates L.C., Siebert S. (Germany, USA, France, Sweden, Switzerland & Canada)

**P29** Patient characteristics and clinical assessments associated with progression from non-radiographic axial spondyloarthritis to ankylosing spondylitis

**P30** Treatment decisions in axial spondyloarthritis are more than treat to target

**P31** Effect of cigarette smoking on inflammatory arthritis in Curdlan administered SKG mice
Park M-C., Lee J-H., Lee E-J., Chang E-J., Kim Y-G. (Korea)

**P32** Oral and gut microbial profile in ankylosing spondylitis treated with secukinumab: Chronic disease related dysbiosis

**P33** Association of demographic and clinical characteristics of patients with familial Mediterranean fever and axial spondyloarthritis with the M694V mutation

**P34** Co-expression of IL17F and IL17A secretion by enthesal resident T-cells and circulating T-cells is preferentially from the CD4 T-cell subset

**P35** Radiographic spinal damage in psoriatic arthritis patients compared to SpA patients

**P36** Antibodies to two novel peptides in new onset axial spondyloarthritis
Ruytinx P., Vandormael P., Luynen E., De Craemer A.S., Van den Bosch F., Elewaut D., Somers V. (Belgium)

**P37** Antibodies of different isotypes to novel peptides in early axial spondyloarthritis
Ruytinx P., Vandormael P., Luynen E., Vanhoof J., Geusens P., Somers V. (Belgium)

**P38** Efficacy and safety of non-pharmacological and non-biological therapy: A systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Ortolan A., Webers C., Sepriano A., Falzon L., Baraliakos X., Landewé R., Ramiro S., van der Heijde D., Nikipherou E. (The Netherlands, Italy, Portugal, UK & Germany)
P39  Upregulation of innate inflammatory pathways in peripheral blood during the preclinical phase of axial spondyloarthritis

P40  SPARCC, MASES, LEI and MEI indexes capture different patients with enthesitis in axial spondyloarthritis, peripheral spondyloarthritis and psoriatic arthritis

P41  Treating spondyloarthritis early: Does it matter? Results from a systematic literature review

P42  Plasma exosomal miRNAs in ankylosing spondylitis: Prospects for biomarkers
Tavasolian F., Inman R.D. (Canada)

P43  Ankylosing spondylitis and the risk of atherosclerotic cardiovascular diseases: A two-sample Mendelian randomization study
Chen S.H., Gu J.R. (China)

P44  A deep learning framework for MRI detection of active inflammatory and structural changes in the sacroiliac joint consistent with axial spondyloarthritis

P45  Treat-to-target strategy implementation in spondyloarthritis patients of real-world clinical practice remains limited despite high disease activity levels: A cross-sectional single-center study
Flouri I.D., Avgoustidis N., Eskitzis A., Repa A., Pateromichelaki K., Pitsigavadis S., Diamantopoulou S., Nikoloudaki M., Terizaki M., Bertisias G., Sidiropoulos P. (Greece)

P46  Safety of guselkumab in patients with active psoriatic arthritis who are bio-naïve or TNFi-experienced: Pooled results from 4 randomized clinical trials through 2 years

P47  Low rates of radiographic progression with 2 years of guselkumab (TREMFYA®), a selective inhibitor of the interleukin-23p19 subunit: Results from a phase 3, randomized, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
Mease P.J., Gottlieb A.B., McInnes I.B., Rahman P., Kollmeier A.P., Xu X.L., Jiang Y., Sheng S., Shawi M., Chakravarty S.D., Lavie F., van der Heijde D. (USA, UK, Canada & The Netherlands)

P48  Consistent long-term guselkumab efficacy across psoriatic arthritis domains irrespective of baseline patient characteristics
McInnes I.B., Tesser J., Schiopu E., Merola J.F., Chakravarty S.D., Rampakakis E., Shiff N.J., Kollmeier A.P., Xu X.L., Shawi M., Lavie F., Bird P., Mease P.J. (UK, USA, Canada, France, Australia)
Poster Session C

Poster session C is during the coffee break of 15.25 – 16.30 hrs on Thursday, September 8. The presenters of the posters P49 through P72 are requested to be present at their posters.

P49  **Examining the impact of disease activity on quality of life in women with axial spondyloarthritis**  
Maguire S., Family Wilson F., Gallagher P., O’Shea F. (Ireland)

P50  **In radiographic axial spondyloarthritis spinal mobility measures correlate well with the whole spine CT Syndesmophyte Score (CTSS)**  

P51  **Low dose computed tomography Hounsfield units: A reliable methodology for assessing changes in vertebral bone density in radiographic axial spondyloarthritis**  
Marques M.L., Pereira da Silva N., van der Heijde D., Reijnierse M., Braun J., Baraliakos X., van Gaalen F.A., Ramiro S. (The Netherlands, Portugal & Germany)

P52  **Is inflammation-driven bone loss associated with two-year bone formation at the same vertebra in axial spondyloarthritis? – A multilevel analysis from the SIAS Cohort**  

P53  **Increased neutrophil frequency in lymph nodes of patients with psoriatic arthritis**  

P54  **Six years treatment with TNF-α inhibitors does not lead to prolonged hypermineralization as assessed by bone turnover markers in patients with ankylosing spondylitis**  
Siderius M., Spoorenberg A., Van der Veer E., Kroese F.G.M., Arends S. (The Netherlands)

P55  **The course of bone mineral density during 8 years of treatment with TNF-α inhibitors in patients with ankylosing spondylitis**  
Siderius M., Spoorenberg A., Wink F.R., Arends S. (The Netherlands)

P56  **Long-term follow-up of starting and switching from original adalimumab to adalimumab biosimilar: Real-world data in axial spondyloarthritis**  
Pinto A.S., Flora K., Matharu D., Isaacs A., Machado P.M. (Portugal & UK)

P57  **Predictors of remission in patients with axial spondyloarthritis: A systematic literature review**  
Pinto A.S., Farisogullari B., Machado P.M. (Portugal, Turkey & UK)

P58  **Differential between IL-6 and IL-17 pathway inhibition in relationship with clinical outcomes in non-biological DMARD-IR and biological DMARD-IR psoriatic arthritis patients treated with upadacitinib in SELECT-Psa 1 and SELECT-Psa 2 studies**  
Cai F., Somasse T., Ruzi M., Fang Y., Kato K., Wung P., McInnes I. (USA & UK)

P59  **Effect of guselkumab (TREMRYA®), a selective IL-23p19 inhibitor, on axial-related endpoints in patients with active PsA: Results from a phase 3, randomized, double-blind, placebo-controlled study through 2 years**  

P60  **Efficacy and safety of biological DMARDs: A systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis**  
Webers C., Ortolan A., Sepriano A., Falzon L., Baraliakos X., Landewé R., Ramiro S., van der Heijde D., Nikiforou E. (The Netherlands, Italy, Portugal, UK & Germany)

P61  **Filgotinib treatment results in reduction of inflammatory and matrix remodeling biomarkers associated with disease in patients with ankylosing spondylitis**  
Maksymowych W., Tian Y., Xu J., Barchuk W., Galien R., Besuyen R., Liu Y., Malkov V., Hertz A. (Canada, USA, France & The Netherlands)

P62  **Serum Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF) is increased in patients with active ankylosing spondylitis (AS) and persists despite anti-TNF treatment**  
Papagoras C., Tsiami S., Chrysanthopoulou A., Mitroulis I., Baraliakos X. (Greece & Germany)
P63 Earlier clinical response predict low rates of radiographic progression in bio-naive active psoriatic arthritis patients receiving guselkumab treatment
Mease P.J., Gottlieb A.B., Ogdie A., McInnes I.B., Chakravarty S.D., Rampakakis E., Kollmeier A.P., Xu X.L., Shawi M., Lavie F., Kishimoto M., Rahman P. (USA, UK, Canada, France & Japan)

P64 Spinal radiographic progression and its association with progression to ankylosing spondylitis in patients with non-radiographic axial spondyloarthritis

P65 Platelet-derived growth factor B is a key element in the pathological bone formation of ankylosing spondylitis

P66 Immunoglobulins are upregulated in psoriatic arthritis skin lesions but not in psoriasis skin lesions
Johnsson H., Cole J., Siebert S., McInnes I.B., Graham G. (UK)

P67 Utility of the subchondral bone attenuation coefficient of the sacroiliac margins to differentiate spondyloarthitis and osteitis condensans ili
Terrier A., Fakih O., Chouk M., Prati C., Wendling D., Aubry S., Verhoeven F. (France)

P68 Whole blood transcriptional changes following treatment with filgotinib in patients with ankylosing spondylitis
Poddubnyy D., Liu Y., Barchuk W., Besuyen R., Galien R., Tian Y., Malkov V., Hertz A. (Germany, USA, The Netherlands & France)

P69 What does it mean – a good response to NSAIDs? A systematic comparison of patients with axial spondyloarthritis and controls with chronic back pain
Baraliakos X., Redeke I., Bergmann E., Tsiami S., Braun J. (Germany)

P70 Guselkumab (TREMFIYA®) maintains resolution of dactylitis and enthesitis in patients with active psoriatic arthritis: Results through 2 years from a phase 3 study

P71 Screening for the early identification of psoriatic arthritis with axial involvement (AXPSA) in a cohort of Italian patients affected by psoriasis (ATTRACT): Preliminary results of a cross-sectional study
Benfaremo D., Paci V., Cimaroli I., Agostinelli A., Sordillo R., Offidani A.M., Moroncini G., Proft F., Poddubny D., Luchetti Gentiloni M.M. (Italy & Germany)

P72 No change in serum levels of bone turnover markers corrected for age and gender during the first year of secukinumab treatment in patients with ankylosing spondylitis
Siderius M., Arends S., Wink F.R., Spoorenberg A. (The Netherlands)
Poster session D is during the coffee break of 10.15 – 11.15 hrs on Friday, September 9. The presenters of the posters P73 through P96 are requested to be present at their posters.

**P73** The ASAS core outcome set for axial spondyloarthritis
Navarro-Compán V., Boel A., Boonen A., Mease P., Dougados M., Kiltz U., Landewé R., van der Heijde D. (Spain, The Netherlands, USA, France & Germany)

**P74** Impact of spine ankylosis on bone fragility evaluated on CT-scan in patients with ankylosing spondylitis
Moritzot C., Fauny M., Allado E., Pinzano-Watrin A., Chary-Valckenaere I., Loeulille D. (France)

**P75** Are α4β7+ γδ T cells prone for the IL-17 and IL-22 secretion in pspondyloarthritis?

**P76** Increased expression of B cell receptor signalling genes in patients with ankylosing spondylitis

**P77** Real-world persistence and treatment patterns in psoriatic arthritis patients treated with anti-IL17 therapy: The PERFIL-17 study

**P78** Treatment with upadacitinib in refractory psoriatic arthritis - Multicenter study of 51 patients of clinical practice

**P79** Impact of patient and disease characteristics on global functioning and health in patients with axial spondyloarthritis: A Bayesian Network analysis of data from an early axSpA cohort
Redeker I., Landewé R., van der Heijde D., Ramiro S., Boonen A., Dougados M., Braun J., Kiltz U. (Germany, The Netherlands & France)

**P80** Development through co-creation of a personalized, multimodal, physiotherapist-led, work-oriented intervention to increase workability in working people with axial spondyloarthritis or rheumatoid arthritis

**P81** Predictors of sustained remission in people with axial spondyloarthritis treated with biologic drugs

**P82** Multi-biologic resistant anterior uveitis in the context of spondyloarthritis
Kougkas N., Dimitroulas T., Avgoustidis N. (Greece)

**P83** Korean treatment recommendations for the patients with axial spondyloarthritis

**P84** Distribution of inflammatory/degenerative/ ambiguous lesions on conventional lumbar lateral radiographs in psoriatic arthritis patients
Ayan G., Sadic A., Kılıç L., Kalyoncu U. (Turkey)

**P85** Electrical treatment on sleep disturbance within autoimmune diseases patients and its effectiveness on immunologic factors
Jiaoshi Z., Jieruo G. (China)

**P86** Adipsin and resistin levels are increased in serum of spondyloarthritis patients
Bernal-Álferes B., Meza-Olguín G., Burgos-Vargas R., Romero-López J.P. (Mexico)

**P87** Electrocardiographic disturbances in psoriatic arthritis - A case-controlled study
Azvedo S.F., Carvalho S., Mazeda C., Silva S.P., Barcelos A. (Portugal)
P88 Machine learning classification of vitamin D levels in spondylo-arthritis patients

P89 Machine learning model of the ultrasound index of MASEI enthesis and other variables of disease activity in patients with spondyloarthritis
Castro Corredor D., Calvo Pascual L.A., Ramírez Huaranga M.A., Garrido Merchán E.C., Paulino Huertas M. (Spain)

P90 Do lateral and AP radiographs tell different story in patients with psoriatic arthritis?
Ayan G., Sadic A., Kılıç L., Kalyoncu U. (Turkey)

P91 Development and validation of a screening tool for spondyloarthritis in Sub-Saharan Africa: SpASSS questionnaire

P92 Self-reported physical activity in patients with axSpA: Adherence to public health recommendations and association with health status in two Dutch cohorts

P93 Applicability of the MASEI index in enthesis and its association with other indices/serological markers of activity in patients with spondyloarthritis

P94 How is early spondyloarthritis defined in the literature? Results from a systematic review
Benavent D., Capelusnik D., van der Heijde D., Landewé R., Podubnyy D., van Tubergen A., Faillon L., Ramiro S., Navarro-Compán V. (Spain, Argentina, The Netherlands, Germany & UK)

P95 Pelvis radiography findings and progression rates in patients with psoriatic arthritis under biologic treatment
Ayan G., Sadic A., Kılıç L., Kalyoncu U. (Turkey)

P96 Clinical characteristics of late-onset ankylosing spondylitis in Korea
Kim M.H. (Republic of Korea)

P97 Translation and cross-cultural adaptation of coping with rheumatic stressors (CORS) into Turkish language
Ayan G., Ramiro S., Pimentel-Santos F.M., Van Lankveld W., Kılıc L. (Turkey, The Netherlands & Portugal)

P98 Work abandonment in patients with ankylosing spondylitis under 45 years of age

P99 Re-induction with certolizumab pegol after secondary loss of response is a valid therapeutic strategy in axial spondyloarthritis and psoriatic arthritis
Conesa Mateos A., Bedoya Sanchís D., Lozano Saez A., Ángel Belmonte Serrano M. (Spain)

P100 Adapting to living with axial spondyloarthritis: Results from the European map of axial spondyloarthritis (EMAS)
Garrido-Cumbera M., Podubnyy D., Bundu C., Makri S., Mahapatra R., Correa-Fernández J., Christen L., Delgado-Domínguez C.J., Navarro-Compán V. (Spain, Germany, UK, Cyprus & Switzerland)

P101 Assessment of the impact of axial spondyloarthritis on patient's social life: Results of the European map of axial spondyloarthritis (EMAS)
Garrido-Cumbera M., Navarro-Compán V., Bundu C., Mahapatra R., Makri S., Correa-Fernández J., Christen L., Delgado-Domínguez C.J., Podubnyy D. (Spain, UK, Cyprus, Switzerland & Germany)

P102 Role of patient organizations in implementation of recommended non-pharmacological treatment modalities in spondyloarthritis: Evidence for the effectiveness of self-management strategies
Meyer-Olson D., Hooper K., Hammel L., Lieb S., Haehle A., Kiltz U. (Germany)

P103 Differences in early-onset vs. Late-onset psoriatic arthritis: Data from the RESPONDIA and REGISPONSER studies

P104 Experience of clinics specialized in multidisciplinary care (MCC) in psoriatic arthritis (APS) in different health systems in Mexico
Registration Fees

<table>
<thead>
<tr>
<th>Congress</th>
<th>Until 30/06</th>
<th>As of 01/07</th>
<th>As of 01/09</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant MD</td>
<td>€ 600,00</td>
<td>€ 650,00</td>
<td>€ 700,00</td>
</tr>
<tr>
<td>Student/researcher non-MD with Abstract*</td>
<td>€ 350,00</td>
<td>€ 400,00</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Industry Participant</td>
<td>€ 800,00</td>
<td>€ 850,00</td>
<td>€ 900,00</td>
</tr>
<tr>
<td>Congress Dinner on Thursday 8 September</td>
<td>€ 75,00</td>
<td>€ 75,00</td>
<td>€ 75,00</td>
</tr>
</tbody>
</table>

The registration fee includes:
- Access to all lectures
- Access to the exhibition
- Coffee breaks and lunches as mentioned in the programme
- Opening Reception & Walking Dinner on Wednesday 7 September
- Farewell Reception on Friday 9 September

Separate registration for the Pre-Congress Review Course on Wednesday 7 September and the Congress Dinner on Thursday 8 September is mandatory.

Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory.

Payment
Payment is to be made by credit card. Only VISA and MasterCard are accepted.

Cancellations
Cancellations received no later than 15 August, entitle registered persons to a 50% refund. In order to cancel your registration and/or hotel booking please contact Sarah Volckaert: sarah@medicongress.com.

Posters on Display

P105 Health-related quality of life measures in axial spondyloarthropathy of recent diagnosis

P106 Axial spondyloarthritis, age and male gender impact COVID vaccination adverse events more than rheumatoid arthritis

P107 Less than expected impact of rheumatoid arthritis and axial spondyloarthritis disease on COVID severity

P108 Prevalence of obesity and its relationship with the level of joint activity in patients with psoriatic arthritis
Moreno Morales J., Albaladejo Paredes G., Pérez González A., Rodríguez Martínez F., Cogolludo Campillo V. (Spain)

P109 The practical utility of superb microvascular imaging technique in evaluation of enthesitis: Pictorial case series
Seskute G., Butrimiene I. (Lithuania)

P110 Tumor necrosis factor receptor associated factor 1 (TRAF1) is a great therapeutic target for RA patients as seen by its opposing effects on monocytes and T lymphocytes
Akram A., Inman R., Abdul-Sater A. (Canada)

P111 Real-life efficacy of upadacitinib in patients with psoriatic arthritis: Preliminary results of a multicentric Italian study
Paci V., Benfaredo D., Gigli M., Sordillo R., Chimenti M.S., Ramonda R., Moroncini G., Luchetti M.M. (Italy)

P112 Turkish translation and cross-cultural adaptation of the modified short questionnaire to assess health-enhancing physical activity (MSQUASH)
Ayan G., Ramiro S., Pimentel-Santos F.M., Spoorenberg A., Arends S., Kilic L. (Turkey, The Netherlands & Portugal)

P113 Electrocardiographic findings in axial spondylarthropathy compared to psoriatic arthritis - A cross-sectional study
Azevedo S.F., Carvalho S., Mazeda C., Silva S.P., Barcelos A. (Portugal)
Hotel Accommodation

A number of hotel rooms have been booked at special group rates, including breakfast and VAT.

The rates are available on the website (https://spa-congress.org/hotel-accommodation) and are only valid for reservations made through Medicongress.

Housing requests are filled in order of receipt. If the hotel of your choice is filled, you will be assigned to another hotel. Hotel availability cannot be guaranteed after August 15.

Any requests for hotel accommodation must be accompanied by a credit card number, in order to secure the room. This credit card will not be charged by the organisers but only serves as a reservation guarantee. Participants will have to pay their hotel room and personal expenses at the reception of the hotel. In case of late cancellation or no show, the room will be charged on the credit card.

A hotel confirmation will be sent by email after receipt of the registration form and housing request and payment of the registration fee.

General Information

Venue
De Bijloke
Bijlokekaai 7
9000 Gent
https://www.bijloke.be/

De Bijloke is located in the city centre, within walking distance from the hotels.

Dates
Wednesday 7 September – Friday 9 September 2022

Language
The official congress language is English.

Exhibition
A medical exhibition is held on the occasion of the Congress. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Catering
Coffee breaks and lunches will be served in the exhibition area.

WiFi
Free WiFi is offered to all participants and exhibitors. The WiFi access code will be available onsite.

Liability
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration
MEDICONGRESS
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 85
Email: congresses@medicongress.com
Platinum Sponsors

abbvie

Lilly

Gold Sponsor

Novartis

Silver Sponsor

Galápagos